NASDAQ:CHRS

Coherus Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy CHRS

*Your capital is at risk

$1.46

-0.0200 (-1.35%)

At Close: Jun 23, 2026

Coherus BioSciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -83.14. In total, the insiders bought 10.54M and sold 3.71M CHRS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-83.14
● Buy	10.54M shares
● Sell	3.71M shares
67% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence May 29, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -83.14. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Karachun Rita A Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Erbez Georgia Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Newton Charles W. Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Satvat Ali J. Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Satvat Ali J. Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Newton Charles W. Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Erbez Georgia Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Karachun Rita A Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Ryan Michael Lee Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Wahlstrom Mats Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	O'donnell-tormey Jill Director	Director	112 000 Value: $88.5K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Newcomer Lee Nisley Director	Director	112 000 Value: $88.5K
May 23, 2025 Sell	Common Stock S-Sale	Wahlstrom Mats Director	Director	99 988 Value: $73.9K
May 23, 2025 Sell	Common Stock S-Sale	Wahlstrom Mats Director	Director	99 988 Value: $73.9K
May 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	200 000 Value: $189.2K
May 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Lanfear Dennis M President & CEO	CEO / President	375 000 Value: $354.8K
May 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Lanfear Dennis M President & CEO	CEO / President	375 000 Value: $354.8K
May 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	200 000 Value: $189.2K
Jan 20, 2025 Sell	Common Stock F-InKind	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	1 711 Value: $2K
Jan 20, 2025 Sell	Common Stock F-InKind	Reider Paul Chief Commercial Officer	Officer	4 858 Value: $7K
Jan 20, 2025 Sell	Common Stock F-InKind	Lanfear Dennis M President & CEO	CEO / President	11 810 Value: $16.4K
Jan 20, 2025 Sell	Common Stock F-InKind	Lanfear Dennis M President & CEO	CEO / President	11 810 Value: $16.4K
Jan 20, 2025 Sell	Common Stock F-InKind	Reider Paul Chief Commercial Officer	Officer	4 858 Value: $7K
Jan 20, 2025 Sell	Common Stock F-InKind	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	1 711 Value: $2K
Jan 10, 2025 Buy	Stock Option (Right to Buy) A-Award	Lanfear Dennis M President & CEO	CEO / President	575 000 Value: $845.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COHERUS BIOSCIENCES

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...

Read Full Profile Here